Perkins Capital Management’s Standard BioTools LAB Stock Holding History

Perkins Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-19,600	Closed	-$70K	–	111
2022 Q1	$70K	Sell	19,600 -460,300	-96%	-$1.59M	0.06%	103
2021 Q4	$1.88M	Sell	479,900 -40,925	-8%	-$192K	1.27%	28
2021 Q3	$3.43M	Hold	520,825	–	–	2.12%	11
2021 Q2	$3.21M	Sell	520,825 -20,000	-4%	-$107K	1.82%	15
2021 Q1	$2.44M	Buy	540,825 +172,425	+47%	+$947K	1.41%	22
2020 Q4	$2.21M	Buy	368,400 +35,975	+11%	+$236K	1.45%	25
2020 Q3	$2.47M	Buy	+332,425	New	+$2.29M	2.27%	11
2020 Q1	$646K	Buy	254,267 +30,684	+14%	+$101K	0.78%	45
2019 Q4	$778K	Sell	223,583 -8,700	-4%	-$30.6K	0.7%	51
2019 Q3	$1.07M	Sell	232,283 -65,517	-22%	-$516K	0.93%	41
2019 Q2	$3.67M	Sell	297,800 -33,350	-10%	-$425K	2.57%	7
2019 Q1	$4.4M	Buy	331,150 +6,350	+2%	+$66.9K	2.9%	6
2018 Q4	$2.8M	Buy	324,800 +106,300	+49%	+$828K	2.17%	9
2018 Q3	$1.64M	Buy	218,500 +49,500	+29%	+$352K	0.98%	31
2018 Q2	$1.01M	Buy	169,000 +15,250	+10%	+$86.9K	0.72%	51
2018 Q1	$898K	Buy	153,750 +21,100	+16%	+$139K	0.81%	45
2017 Q4	$781K	Buy	+132,650	New	+$726K	0.75%	47

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Perkins Capital Management's LAB Position: Q2 2022 in Review

Perkins Capital Management sold out of Standard BioTools (LAB) in Q2 2022, closing a stake of 19,600 shares — an estimated $70K sold.

Perkins Capital Management first reported a position in LAB in Q4 2017 and held it in 17 quarters. The position peaked at $4.4M in Q1 2019. 86 funds tracked by Wall St. Rank hold LAB as of Q2 2022.

Perkins Capital Management reported no remaining Standard BioTools position as of Q2 2022 after selling out during the quarter.
Perkins Capital Management sold 19,600 Standard BioTools shares in Q2 2022, an estimated $70K.
Perkins Capital Management first reported a position in Standard BioTools in Q4 2017 and held it in 17 quarters.
Perkins Capital Management's Standard BioTools position peaked at $4.4M in Q1 2019.
86 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2022.

Based on Perkins Capital Management's 13F filing for Q2 2022, filed 29 Jul 2022.